Amgen's Q1 2016 earnings call highlighted strong financial performance, with revenue and EPS growth exceeding expectations.  Management emphasized successful product launches, particularly in the oncology and cardiovascular franchises, and projected continued growth in international markets.  The updated guidance reflects a positive outlook for the year, potentially signaling a short-term positive stock price impact.
[1]
